Skip to main content
IntegraGen logo

IntegraGen — Investor Relations & Filings

Ticker · ALINT ISIN · FR0010908723 LEI · 969500CQD8K0BUIGDH55 PA Professional, scientific and technical activities
Open in API
Filings indexed 160 across all filing types
Latest filing 2026-04-10 Earnings Release
Country FR France
Listing PA ALINT

About IntegraGen

https://integragen.com/

IntegraGen, an OncoDNA company, specializes in translating molecular research into clinical practice, with a primary focus on cancer genomics and rare genetic diseases. The company provides comprehensive genomic services, including Next-Generation Sequencing (NGS) and advanced bioinformatics analysis, to academic researchers, biopharmaceutical companies, and clinical research organizations. Operating from a CLIA/CAP-certified laboratory, IntegraGen is a key genomics partner for oncology clinical trials. Its core mission involves identifying novel genetic biomarkers to develop and commercialize molecular diagnostic tests, delivering interpretable genomic data to advance both research and patient care.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 92% confidence The document is a press release dated April 10, 2026, titled “Résultats annuels 2025,” providing bullet-point highlights of revenue, cash, and key ratios, followed by condensed financial statements (income statement, balance sheet, cash flow) and management commentary. It is the initial public announcement of the company’s annual financial results, consistent with an Earnings Release. Therefore, it should be classified as ER (Earnings Release). FY 2025
2026-04-10 French
Informations privilégiées / Information sur chiffre d’affaires annuel
Earnings Release Classification · 100% confidence The document is a press release titled 'COMMUNIQUE DE PRESSE' announcing the company's annual revenue (chiffre d'affaires) for 2025, cash position, and strategic updates. It explicitly states that the full annual financial results will be published at a later date (April 30, 2026). Since this is an initial announcement of key financial highlights rather than the full annual report, it is classified as an Earnings Release (ER). FY 2025
2026-02-20 French
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 100% confidence The document is a press release titled 'Résultats du 1er semestre 2025' (H1 2025 Results) issued by IntegraGen. It provides a summary of financial performance, including income statements and balance sheet data for the period ending June 30, 2025. While it contains financial tables, it is structured as an initial announcement of periodic results (Earnings Release) rather than a full comprehensive interim report or a report publication announcement. Therefore, it fits the definition of an Earnings Release (ER). H1 2025
2025-10-29 French
Informations privilégiées / Autres communiqués
Regulatory Filings
2025-10-21 French
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 100% confidence The document is a press release announcing that IntegraGen has initiated a 'procédure de sauvegarde' (safeguard procedure) due to financial difficulties. This is a significant corporate event regarding the company's financial stability and legal status. Since it does not fit into specific categories like M&A, share issuance, or earnings releases, and serves as a formal regulatory announcement to the market, it is best classified as a Regulatory Filing (RNS).
2025-10-06 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release from IntegraGen providing an update on business activity, cash position, and a board deliberation regarding potential restructuring or safeguard procedures. It contains financial highlights (revenue, cash position) and forward-looking statements about liquidity. It does not constitute a full financial report (10-K or IR) but rather an ad-hoc regulatory announcement regarding the company's financial health and strategic direction. Given the nature of the disclosure regarding financial distress and board actions, it fits best as a general regulatory filing (RNS) or a management update on business trends (MDA). However, as it is a press release announcing these specific developments, RNS is the most appropriate classification for this type of corporate disclosure. H2 2025
2025-09-19 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.